StockNews.AI
WST
StockNews.AI
201 days

West to Host Fourth-Quarter and Full-Year 2024 Conference Call

1. West Pharmaceutical will announce Q4 and FY2024 results on February 13, 2025. 2. A conference call will follow to discuss results and business expectations. 3. West generated $2.95 billion in net sales in FY 2023. 4. The company provides innovative injectable solutions and serves over 10,000 employees globally. 5. Live webcast and replay available for 90 days post-conference call.

4m saved
Insight
Article

FAQ

Why Neutral?

Earnings announcements typically stabilize stock prices without significant volatility.

How important is it?

Earnings reports are crucial for understanding company performance, influencing investor sentiment.

Why Short Term?

Immediate market reactions expected during the earnings release period.

Related Companies

WST
EXTON, Pa., Jan. 30, 2025  /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST),  global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2024 financial results before the market opens on Thursday, February 13, 2025, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time. The live webcast will be made available via the Company's Investor Relations website or by clicking here. To ask questions on the conference call, participants need to register in advance by clicking here.  Registered telephone participants will receive the dial-in number along with a unique PIN number that will enable them to ask questions on the call. A slide presentation will be made available on the day of the call in the Investors section of the Company's website. A replay of the conference call and webcast will be available on the Company's website.  Replay of the webcasts will be available for approximately 90 days after the events. About West West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With over 10,000 team members across 50 sites worldwide, West helps support our customers by delivering approximately 43 billion components and devices each year. Headquartered in Exton, Pennsylvania, West in its fiscal year 2023 generated $2.95 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com. All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted. SOURCE West Pharmaceutical Services, Inc.

Related News